Severe cholestasis related to intraconazole for the treatment of onychomycosis. uri icon

Overview

abstract

  • We describe a case of prolonged cholestasis temporally associated with the use of itraconazole for onychomycosis. Peak bilirubin level of 32.0 mg/dl was documented approximately 2 months after discontinuation of the patient's itraconazole therapy, with symptoms of cholestasis persisting more than 1 month after the peak in bilirubin. Physicians should be aware of the potential for severe cholestasis associated with itraconazole usage.

publication date

  • December 1, 1999

Research

keywords

  • Antifungal Agents
  • Cholestasis, Intrahepatic
  • Itraconazole
  • Onychomycosis

Identity

Scopus Document Identifier

  • 0032779118

PubMed ID

  • 10606333

Additional Document Info

volume

  • 94

issue

  • 12